**MINUTES**

**CPIC CONFERENCE CALL**

DATE: December 5, 2013

PRESENT: Adriana Malheiro, Andrea Gaedigk, Dan Hertz, Daniel Muller, David Kisor, Ellie McDonagh, James Hoffman, Jasmine Talameh, Javier Blanco, Jeff Bishop, Julia Barbarino, Tom Callaghan, Kris Crews, Kelly Caudle, Li Gong, Marc Williams, Mary Relling, Matthias Schwab, Mia Wadelius, Michelle Whirl-Carrillo, Robert Freimuth, Steve Leeder, Stuart Scott, Sunda Ubri, Teri Klein, Todd Skaar, Uli Broeckel, Vojtech Huser

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| CPIC email addresses | CPIC/PharmGKB created a new email list for cpic-related discussions - cpic-discussion@lists.stanford.edu. This is an opt-in email list which you can customize to receive daily or weekly digests if you prefer. This email list is set up for any type of discussion related to tests, assays, or questions that people would like to send to the group, not directly related to a CPIC guideline or project.  We are reserving the cpic-list@pharmgkb.org email list for meeting announcements, minutes, etc. and emails sent using this list is restricted to the administrators of CPIC. All CPIC members will remain on this email list with no further action. | CPIC members will receive an email regarding this issue. Please reply if you wish to be added to the discussion email list. |
| Update on CPIC guidelines in progress | - *CFTR*/ivacaftor: In revision with CPT  -*G6PD/*rasburicase guideline: see below  - *IL28B*/pegIntron: accepted; published on-line  *- CYP2C9*/ *HLA-B*/phenytoin: Writing underway.  -*CYP2D6*/SSRI: Finalizing authorship plan to submit to CPIC Steering Committee  -*CYP3A5*/tacrolimus: CPIC Steering Committee approved authorship plan; Evidence review underway  Guideline Updates:  -Codeine guideline update: in revision with CPT  -*HLA-B*/abacavir: submitted to CPT  -*SLCO1B1*/simvastatin: Will be a major update (update to manuscript and supplement); underway | Kelly will follow-up on progress. |
| *G6PD*/Rasburicase CPIC guideline | Mary Relling (first author) discussed the *G6PD*/Rasburicase guideline, specifically Table 1 and Table 2. CPIC members provided feedback. Plan to submit this guideline to *CPT* in late December/early January. Will circulate the guideline to CPIC members for review and feedback. | Kelly will circulate final guideline draft to CPIC members for comments/edits. Please send all guideline comments/edits to [Kelly.caudle@stjude.org](mailto:Kelly.caudle@stjude.org) by December 20th. |
| CPIC informatics working group update | -Working group roster includes 15 CPIC members from 9 different organizations  -Clinical implementation resources added to abacavir CPIC guideline update (submitted). These resources will serve as templates for future guidelines.  -Work ongoing for these resources on next two guidelines (SLCO1B1/Simvastatin update and CYP2C9/HLA-B/Phenytoin); CPIC informatics members will participate as part of guideline writing group because these are more complex gene/drug pairs and changes/improvements may be required. | CPIC informatics working group leadership will continue to give updates. |